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Abstract
Background There has been a widely documented and
recognized increase in diabetes prevalence, not only in
high-income countries (HICs) but also in low- and middle-
income countries (LMICs), over recent decades. The eco-
nomic burden associated with diabetes, especially in
LMICs, is less clear.
Objective We provide a systematic review of the global
evidence on the costs of type 2 diabetes. Our review seeks
to update and considerably expand the previous major re-
view of the costs of diabetes by capturing the evidence on
overall, direct and indirect costs of type 2 diabetes
worldwide that has been published since 2001. In addition,
we include a body of economic evidence that has hitherto
been distinct from the cost-of-illness (COI) work, i.e.
studies on the labour market impact of diabetes.
Methods We searched PubMed, EMBASE, EconLit and
IBSS (without language restrictions) for studies assessing
the economic burden of type 2 diabetes published from
January 2001 to October 2014. Costs reported in the in-
cluded studies were converted to international dollars ($)
adjusted for 2011 values. Alongside the narrative synthesis
and methodological review of the studies, we conduct an
exploratory linear regression analysis, examining the fac-
tors behind the considerable heterogeneity in existing cost
estimates between and within countries.
Results We identified 86 COI and 23 labour market
studies. COI studies varied considerably both in methods
and in cost estimates, with most studies not using a control
group, though the use of either regression analysis or
matching has increased. Direct costs were generally found
to be higher than indirect costs. Direct costs ranged from
$242 for a study on out-of-pocket expenditures in Mexico
to $11,917 for a study on the cost of diabetes in the USA,
while indirect costs ranged from $45 for Pakistan to
$16,914 for the Bahamas. In LMICs—in stark contrast to
HICs—a substantial part of the cost burden was attributed
to patients via out-of-pocket treatment costs. Our regres-
sion analysis revealed that direct diabetes costs are closely
and positively associated with a country’s gross domestic
product (GDP) per capita, and that the USA stood out as
having particularly high costs, even after controlling for
GDP per capita. Studies on the labour market impact of
diabetes were almost exclusively confined to HICs and
found strong adverse effects, particularly for male em-
ployment chances. Many of these studies also took into
account the possible endogeneity of diabetes, which was
not the case for COI studies.
Conclusions The reviewed studies indicate a large eco-
nomic burden of diabetes, most directly affecting patients in
LMICs. The magnitude of the cost estimates differs consid-
erably between and within countries, calling for the contex-
tualization of the study results. Scope remains large for
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adding to the evidence base on labour market effects of dia-
betes in LMICs. Further, there is a need for future COI studies
to incorporate more advanced statistical methods in their
analysis to account for possible biases in the estimated costs.
Key Points for Decision Makers
The evidence documenting the large—and at least
partly avoidable—economic burden of type 2
diabetes has grown rapidly in the past 13 years.
Many studies documenting the economic costs of
type 2 diabetes in low- and middle-income countries
(LMICs) have emerged, providing a first picture of
the economic impact of diabetes in poorer countries,
whereas the evidence on the labour market effects in
LMICs remains scarce.
Costs of diabetes, as well as its adverse labour
market effects, increase over time and with disease
severity, indicating that early investments into
prevention and disease management may be
particularly worthwhile.
COI studies in particular did not rigorously account
for potential biases in their estimation, suggesting
that cost-effectiveness studies that make use of these
estimates might under- or overestimate the value for
money of the respective intervention or drug.
1 Introduction
Diabetes is a chronic disease that has spread widely, not
only in high-income countries (HICs) but also in many
low- and middle-income countries (LMICs) over recent
decades. The most recent data from the International Dia-
betes Federation (IDF) indicate that diabetes affected 382
million people worldwide in 2013, a number that is ex-
pected to grow to 592 million by 2035. The estimated
global prevalence in 2013 amounts to 8.3 % among people
aged 20–79 years, with the world’s most populous coun-
tries, India and China, reaching prevalence rates between 9
and 10 %, corresponding to 65 and 100 million in absolute
numbers, respectively. Particularly high prevalence rates
are found in Mexico (12.6 %) and Egypt (16.8 %), sur-
passing the rates of most HICs, including the USA (9.2 %)
and Germany (8.2 %) [1]. Taken together, in 2013 about
two-thirds of all individuals with diabetes lived in LMICs
[1]. The rising prevalence of diabetes in LMICs appears to
be fuelled by rapid urbanization, nutrition transition and
increasingly sedentary lifestyles [2]. The most prevalent
form of diabetes by far is type 2 diabetes, affecting about
90 % of people with diabetes, while the remaining 10 %
mainly have type 1 diabetes or gestational diabetes [1].
Due to its adverse effect on people’s health, diabetes
also imposes an economic burden on individuals and
households affected as well as on healthcare systems. The
economic burden of diabetes was confirmed by Ettaro et al.
[3] in a review of cost-of-illness (COI) studies on diabetes
mellitus, published in 2004, covering the literature up to
the year 2000. The authors concluded that the direct and
indirect economic burden of diabetes was ‘‘large’’, and that
costs had increased over time. However, the review also
noted that significant variation in costing methodologies
made it near impossible to directly compare the cost esti-
mates. However, the studies reviewed by Ettaro et al. [3]
were almost exclusively focused on the USA, with a small
number coming from European HICs and none from
LMICs. The aim of this study is therefore to systematically
review the literature on the economic costs of diabetes
published since 2001 (i.e. the first year not covered by the
Ettaro et al. [3] review), as we expect a considerable
number of new studies, also from LMICs. In addition to the
COI studies, we review the literature on labour market
outcomes, with a specific interest in the methodological
challenges involved. In doing so, we substantively update
and expand the scope of the Ettaro et al. [3] review, al-
lowing us to revisit its findings regarding the evidence base
about the economic burden of type 2 diabetes globally.
COI studies generally assess the direct and indirect costs
of a particular illness, where the former represent the op-
portunity cost of resources used for treatment. The indirect
costs measure the value of resources lost due the illness,
most commonly those caused by losses in productivity due
to mortality and morbidity as measured in lost earnings [4].
In addition, another approach also focuses on estimating
the impact of diabetes on labour market outcomes. How-
ever, rather than trying to estimate the monetary losses that
arise from a decrease in productivity, these studies
typically compare labour market outcomes (e.g. employ-
ment probabilities, earnings or lost work days) between
people with and without diabetes, while accounting for
differences in age, education and other demographic and
socioeconomic variables, that might arise between both
groups and that could affect labour market outcomes as
well as the chances of developing diabetes. The aim of
studies in this field is to obtain a clearer picture of how
diabetes causally affects these labour market outcomes,
without necessarily monetizing the results. Because of the
different methodologies and data requirements, these
studies tend to differ considerably from traditional COI
studies, which is why we reviewed them separately. To the
best of our knowledge, this is the first review that sys-
tematically assesses the studies in this particular field.
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2 Methods
PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) guidelines were used as a basis
for the overall study approach [5].
2.1 Search Strategy
The electronic search was based on the following search
terms: ‘Diabetes Mellitus’ [Mesh] AND (‘Costs and Cost
Analysis’ [Mesh] OR ‘Cost of Illness’ [Mesh] OR ‘Em-
ployment’ [Mesh] OR ‘Labor Market’ [All fields] OR
‘Labour Market’ [All fields] OR ‘Productivity’ OR
‘Willingness to pay’ [All fields]). The above search was
run in PubMed and was then adapted for searches in
EMBASE, EconLit and the International Bibliography of
the Social Sciences (IBSS). The search was carried out
from October 2012 to October 2014 and restricted to
studies published between January 2001 and October 2014,
as the earlier review had covered COI studies until 2000
[3]. No language restrictions were applied. The references
were downloaded in RIS format where possible and then
transferred to Mendeley. Authors were contacted for fur-
ther information if clarification was needed after the full-
text analysis.
2.2 Inclusion and Exclusion Criteria
Studies were eligible if a monetary estimate of the direct
and/or indirect costs of diabetes was presented in the re-
sults section or if studies provided an estimate of the im-
pact of diabetes on labour market outcomes (employment
chances, labour income, wages and lost work days). We did
not exclude studies with a small sample size, as this might
have discriminated against studies in LMICs. Studies on
types of diabetes explicitly different from type 2 diabetes
were excluded. However, we included studies that did not
explicitly mention the type of diabetes, given that type 2
diabetes accounts for about 90 % of all diabetes cases.
Studies exclusively assessing the costs of diabetes com-
plications or the costs of management strategies were ex-
cluded as were studies estimating the costs for specific
groups with diabetes (e.g. costs for people with poorly
controlled diabetes), since we were interested in the costs
incurred to populations comprising the whole spectrum of
people with type 2 diabetes. Editorials and reviews and
studies for which the full text could not be retrieved or only
an abstract was available were also excluded.
2.3 Data Extraction and Analysis
Data extraction was carried out by two investigators (TS
and OA). After duplicates were removed, titles and
abstracts were scanned by one researcher (TS) to identify
studies suitable for a full-text review. The process was
checked by a second researcher (OA) on a random sub-
sample of 2,000 studies of the retrieved references. The full
text was subsequently retrieved for the identified studies,
and they were reviewed by two researchers (TS and OA),
with disagreements resolved by discussion. Finally, 109
studies were identified (see Fig. 1) that fulfilled the inclu-
sion criteria, and data extraction was carried out using a
pre-defined extraction table. Primary outcomes were the
total costs, the direct costs, and the indirect costs of type 2
diabetes and the respective per capita estimates of these
outcomes, as well as the impact of type 2 diabetes on
employment chances, income, wages and lost work days.
Secondary outcomes comprised the methodology used to
assess the monetary costs of type 2 diabetes, the range of
cost factors included in the analysis, as well as the
methodology used to assess the labour market impact of
diabetes. Further extracted information included the year of
publication, year of data collection, the time horizon, the
country or region studied, the data source, sample size and
age as well as information on whether the study distin-
guished between types of diabetes.
We present the COI study results in per capita values to
facilitate comparability across countries. For studies pre-
senting overall population level estimates rather than per
capita costs information, we calculated those costs, when-
ever possible, using the diabetes prevalence mentioned in
the respective study. If no total cost estimate was presented
but information on direct and indirect costs was available,
then direct and indirect costs were added up to produce a
total cost estimate. We converted costs into purchasing
power parity (PPP) adjusted estimates, also called inter-
national dollars and henceforth denoted with the $ sign, in
order to further increase comparability. Since some studies
did not present the data in the country’s local currency but
in US$ or some other major currency, we used the ex-
change rate given in the article to convert the estimates
back into the local currency. If no exchange rate was
provided in the study itself, we used the average exchange
rate (midpoint exchange rate according to OANDA his-
torical exchange rates [http://www.oanda.com/currency/
historical-rates/]) for the reported year. The PPP-adjusted
estimates for the year 2011 were then calculated using the
Campbell and Cochrane Economics Methods Group Evi-
dence for Policy and Practice Information and Coordina-
tion Centre (CCEMG-EEPPI Centre) cost converter [6].
For all additional analyses carried out in the following
sections, only studies for which a mean cost estimate was
presented or could be calculated were included. Further, in
the case of a study presenting estimates for more than
1 year, only the estimate for the most recent year was used
for the analysis. For studies presenting both incremental
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and total cost estimates, only the incremental cost estimate
was taken into account.
Studies were further classified into two groups accord-
ing to the level of economic development of the investi-
gated country—(1) high-income and (2) low- and middle-
income countries (LMICs)—according to the historical
World Bank income group classification of the respective
country in the year that data collection for the respective
study had taken place [7]. Where necessary due to space
constraints, we used abbreviations for country names, as
detailed in Table 7.
In order to explore the factors involved in the variation
of direct costs reported in COI studies, we first plotted the
direct per capita costs in relation to the gross domestic
product (GDP) per capita of the respective country and
provided an estimate of the relationship using linear re-
gression. We then conducted an exploratory regression
analysis, with the annual direct cost per patient as the de-
pendent variable to investigate what other factors might
explain the variation in direct cost estimates. The set of
independent variables comprised (1) the estimation ap-
proach in each study, (2) the year of data used, (3) the GDP
per capita of the studied country in international dollars, (4)
an indicator of whether the study was conducted in the
USA, (5) an indicator of whether the study was deemed to
be nationally representative, and (6) a variable indicating
whether the study had explicitly taken diabetes-related
complications into account. The year of the used data was
considered because the development of social security
systems and treatment methods may affect how the direct
costs evolve over time. We categorized this variable into
groups: studies using data from before 1995, 1995–1999,
2000–2004, 2005–2009 and 2010–2014. The dummy
variable for studies on the USA was included to account for
the generally higher healthcare expenditures in the USA
compared with other HICs with similar per capita income
levels [8]. Accounting for national representativeness
should cancel out any effects that might be driven by those
studies that estimate costs for sub-national-, regional- or
city-level population samples. Including an estimator for
diabetes complications should account for the possible
underestimation of diabetes costs in studies excluding
complications. We exclude country estimates extracted
from multi-country studies in our preferred specification, as
their inclusion would lead to an over-statement of the cost
effect of the estimation method employed in the given
multi-country study.
3 Results
Due to the differences in methodologies, we first present
the findings on the identified COI studies and subsequently
turn to studies on labour market outcomes.
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Fig. 1 PRISMA [5] flowchart.
COI cost of illness, PRISMA
Preferred Reporting Items for
Systematic Reviews and Meta-
Analyses
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3.1 Cost-of-Illness (COI) Studies on Type 2 Diabetes
3.1.1 Number of Studies
We identified a total of 86 relevant COI studies (see Table
EMS_1 in the Electronic Supplementary Material [EMS] 1
for a detailed description of the included studies), of which
62 focused on HICs, 23 on LMICs, and one multi-country
study covered both HICs and LMICs. Studies on LMICs
increased over time, with the majority of the LMIC studies
being published between 2007 and 2014. Six of the se-
lected studies were multi-country studies, of which two [9,
10] did not provide detailed cost estimates for every
country in the study and one did not provide a year for the
estimated costs, so that we could not calculate estimates in
international dollars [11]. Therefore, we could not include
these particular studies in our country-specific analysis.
3.1.2 Regional Distribution
In terms of geographic regions, most studies were carried
out on countries in Latin America and the Caribbean
(n = 38) and Europe (n = 37), followed by the USA and
Canada (n = 26), East Asia and Pacific (n = 11), the
Middle East and North Africa (n = 5), South Asia (n = 4),
Sub-Saharan Africa (n = 4) and Australia (n = 1).1 The
USA was the most studied country (n = 19), followed by
Canada (n = 7) and Germany (n = 5). Mexico (n = 6)
and China (n = 4) were the most frequently studied
LMICs.
3.1.3 Data Sources
Especially in LMICs, self-administered surveys represent-
ed a popular method to retrieve data on the cost of diabetes.
These were mostly limited regionally, i.e. to a city or
hospital, and usually only representative of these regional
diabetes populations but not of a national population. In
HICs, databases of insurance and healthcare providers were
the main source of information in most studies. These data
tended to be representative, either at a national or at some
sub-national level. As a result, the size of the samples in
HICs was mostly between 1,000 and several million. By
contrast, studies in low- and lower-middle-income coun-
tries were generally characterized by smaller sample sizes,
ranging from 35 [12] to about 2,433 [13] in the studies
reviewed here.
3.1.4 Variation in Costing Approaches
As discussed in more detail in the Text Box in ESM 2, a
range of costing approaches can be found in the COI lit-
erature. Figure 2 shows that the most common costing
method for the direct costs of diabetes in HICs was the
sum-all medical approach for people with diabetes without
using control groups [9, 11, 14–40]. The disease-at-
tributable costing approach [12, 41–54] and the at-
tributable-fraction approach was also used widely,
although mainly in the USA [55–61]. The incremental cost
approach was applied primarily in studies on HICs [10, 13,
51, 60, 62–79]. For LMICs, the survey approach was the
most used [80–92].
By contrast, almost all indirect cost assessments fol-
lowed the same methodology, i.e. the human capital ap-
proach. This approach considers all forgone labour
earnings of a patient or caregiver that are attributable to
diabetes. A minority of three studies [91, 93, 94] estimated
the indirect costs using the willingness-to-pay (WTP) ap-
proach, which tries to measure how much individuals
would be willing to pay to reduce the risk of an illness [4],
here diabetes (or certain complications associated with it).
One of the studies included WTP estimates in addition to
the direct and indirect costs measured by the human capital
approach [91] but did not include the WTP estimate in the
Fig. 2 Number of cost-of-illness studies, by costing approach and
income group. For LMICs, no WTP study is counted, because the
only study [91] presenting a WTP estimate for an LMIC used
primarily a different approach to estimate costs, and the WTP
estimate was only presented additionally. Therefore, this study was
not counted under WTP here. Two studies are counted twice as they
give estimates for a sum-diagnosis specific and a RB/matching
approach. LMIC low- to middle-income country, RB regression
based, WTP willingness to pay
1 The number of countries studied is higher than the number of
articles reviewed due to four multi-country studies estimating costs
for multiple countries [11, 14, 15, 41].
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overall cost estimate, while the other two studies estimated
exclusively the WTP [93, 94].
3.1.5 Study Perspective
Studies also varied in their perspective, again compro-
mising direct comparability of the cost estimates across
studies. Overall, most studies either took a societal
(n = 32) or healthcare system perspective (n = 48). The
former generally takes into account the direct and indirect
monetary costs that arise to society, including costs to the
healthcare system, costs due to lost productivity and
sometimes out-of-pocket (OOP) costs [4]. The latter was
especially common in HICs, where many studies assessed
the cost of diabetes to private or public health insurances.
In LMICs, studies often took the patient perspective (n =
5), estimating OOP expenditures and in some cases pro-
ductivity losses, directly arising to the diabetes patient.
3.1.6 Costing Components
Of the 75 studies that reported the cost components they
used to estimate direct costs, 72 took into account outpa-
tient hospital visits, 70 inpatient hospital visits, 63 physi-
cian visits, 58 drug costs, 51 laboratory costs for diagnostic
tests and check-ups, 37 equipment costs and 21 non-med-
ical and transportation costs. A total of 46 studies had at
least included the costs of hospital, outpatient and physi-
cian visits as well as drugs (see Table EMS_3 in ESM 3 for
a detailed description of cost components used in each
study).
3.1.7 Cost Estimates of Diabetes Using a Prevalence
Approach
Two basic epidemiological approaches exist for the esti-
mation of COI, and they are not directly comparable. The
incidence approach follows people with diabetes, usually
starting with their diagnosis at a common base year, esti-
mating yearly costs for a sample of people at the same
disease stage, finally giving an estimate of diabetes costs
over a certain time period, such as from diagnosis to death
or over a distinct period of, for example, 10 years. This
approach can also document how costs of diabetes change
and develop over the progression of the disease [96]. By
contrast, the prevalence approach estimates the costs of
diabetes for a cross-section of people with diabetes at a
certain point in time, normally a year, who are at different
stages of the disease. It is most suitable for assessing the
total economic burden of diabetes at a certain point in time.
Due to this difference in time periods and the used data, the
estimates of prevalence-based studies are not directly
comparable with those of incidence-based studies. Hence,
we present the cost estimates separately, starting with the
prevalence approach.
Table 1 shows the range of direct cost estimates by es-
timation approach and income status. As can be observed,
direct cost estimates varied widely, both between and
within the different estimation approaches. Cost estimates
for direct costs, irrespective of the costing method applied
and the cost components included, ranged from $242 for
Mexico [28] in 2010 to $11,917 for the USA [36] in 2007.
Also, studies from LMICs generally indicated smaller di-
rect costs than studies from HICs.
For indirect costs, studies using the human capital ap-
proach estimated costs ranging from $45 for Pakistan [85]
in 2006 to $16,914 for the Bahamas [14] in 2000. Three
studies estimated indirect costs by using the WTP approach
and found costs ranging from $191 in a study on the WTP
for health insurance for type 2 diabetes in Denmark in 1993
[94], a WTP $4,004 per year for a cure of type 2 diabetes
[93] in Taiwan and an annual payment of $4,737 to halt
disease progression/prevent future complications of dia-
betes in India [91].
Societal costs of type 2 diabetes, which are estimated by
studies combining direct and indirect costs, ranged from
$544 in a study on the economic costs of diabetes in Iran
[67] in 2001 to $18,224 for the Bahamas [14] in 2000.
In order to improve the cross-country comparability of
the costs of diabetes, we plotted the results from studies
providing a direct per capita cost estimate against the GDP
per capita estimate of the respective country (we limited
this comparison to studies using samples representative of
their entire population). Figure 3 confirms the expectation
that costs do increase with economic wealth: GDP per
capita explains about one-third of the variation in cost es-
timates (see r2 in Fig. 3). Also, studies on the USA seem to
estimate costs consistently higher than would be expected
on the basis of its GDP per capita.
Again, the wide variation in estimated costs for many
countries underscores the point that the studies need to be
contextualized and may not be directly comparable per se.
On the whole—though by no means always—the matching
and regression as well as the sum-diagnosis specific ap-
proaches appear to produce lower cost estimates than
especially the total cost results, particularly so for HICs. In
an inevitably crude attempt to quantitatively explore the
driving factors behind the heterogeneity in cost estimates,
we estimated a simple linear regression model with per
capita direct costs as the dependent variable; explanatory
variables included GDP per capita, the estimation approach
employed by the study, the number of included cost
components, a dummy for studies carried out in the USA,
the year of data collection, the representativeness of the
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study and whether the study included diabetes complica-
tions. The results, displayed in Table 2, show a strong re-
lationship between GDP per capita and expenditures for
diabetes, with every additional international dollar in per
capita GDP translating into an average increase in direct
diabetes expenditures of about $0.04. The estimation ap-
proach is not found to matter significantly, nor is the year
of study. Estimates from USA studies put the costs at over
$3,000 higher (on average) than studies from other coun-
tries, indicating that costs in the USA may indeed be
unusually high. The number of costing components and the
inclusion of complications likely also explain some of the
variance in estimates, although they are just below and
above the 10 % significance level, respectively. Overall,
the included independent variables explain about 56 % of
the variation in direct cost estimates.2
The sensitivity of the cost results to the estimation ap-
proach was also examined by two studies that investigated
the effect of different estimation techniques in diabetes
COI studies. Honeycutt et al. [60] compared the use of a
regression-based and an attributable-fraction approach and
Fig. 3 GDP to direct costs ratio
by estimation approach. The
line depicts the best fit based on
the linear regression of direct
costs on GDP per capita in
international dollars. Refer to
Table 7 for country
abbreviations. For better
visibility, the y-axis presenting
per capita direct costs is
expressed in log scale. GDP
gross domestic product
Table 1 Summary of direct costs by estimation approach and income status in international dollars $ (2011) for prevalence-based studies
High-income countries Low- and middle-income countries
Sum-all medical
costs
Sum-diagnosis
specific
RB/matching Own
survey
Sum-all medical
costs
Sum-diagnosis
specific
RB/matching Own
survey
Min 1,117 907 264 1,495 242 662 443 456
Max 11,917 9,346 8,306 5,585 4,129 4,672 1,136 3,401
N 25a 19a 18 3 27a 5a 2 10
RB regression based
a Includes country estimates from multi-country studies
2 In a sensitivity analysis, we included the results from multi-country
studies providing country estimates in the regression analysis. The
only major difference to the presented analysis is that the inclusion of
complications as well as the number of included cost components
were now significant at the 1 and 5 % significance level, respectively.
The effect size and significance of the other estimates did not change
considerably.
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found that the cost estimate of the former exceeded the
latter by 43 %. Tunceli et al. [51] compared the matching
and the diabetes (disease) attributable costs approach and
found a 14–29 % higher cost estimate using matching,
depending on the used assumptions. Both studies con-
cluded that an incremental cost approach results in a
higher, and likely more exact, estimate of the direct costs
of diabetes than disease-attributable approaches. The au-
thors attributed this to the fact that a regression or matching
approach can assign costs to diabetes that cannot be linked
to diabetes otherwise. Those approaches are therefore in a
position to account for all costs of co-morbidities caused by
diabetes, while this is not automatically the case with the
other approaches.
3.1.8 Direct and Indirect Costs of Diabetes
To assess the relative importance of direct and indirect
costs across countries, we plotted direct against indirect
costs from studies that provided both estimates and drew a
45 line depicting the equal share of direct and indirect
costs (see Fig. 4).
Most studies found a larger share for direct costs in
comparison with indirect costs (observations above the 45
line in Fig. 4). This is especially true for HICs, where only
a study on Sweden [59] found a larger share for indirect
costs. For LMICs, a study on Colombia [19] found con-
siderably higher indirect costs, as did the multi-country
study of Barcelo´ et al. [14] and a study on various countries
in the African region [9], which both found higher indirect
costs for almost every country in the study and also on
average for the entire regions, represented as the mean
overall study estimate in Fig. 4. Both studies used similar
approaches to estimate costs, and indirect cost estimates
were likely so high because evidence from only a few
countries within the region were used as a basis for esti-
mating indirect costs for every other country in the re-
spective study. Further, the studies took the countries’ per
capita gross national product as a proxy for earnings, which
might have led to an over-estimation of the indirect costs
[9].
3.1.9 Studies Using the Incidence Approach
The four studies that used an incidence approach (see
Table 3) estimated the cost of diabetes either over a per-
son’s lifetime [19, 73] or over a certain period after diag-
nosis [21, 52]. Gonza´lez et al. [19] modelled the lifetime
(direct and indirect) costs of a typical diabetes patient in
Colombia, arriving at a mean cost estimate of $54,000. The
second study providing lifetime estimates, by Birnbaum
et al. [73], estimated incremental lifetime healthcare costs
for USA females with diabetes of $283,000.
Two studies followed patients over a limited time period
and found different patterns in the development of type 2
diabetes-attributable healthcare costs. In Germany, costs
increased from $1,634 in the first year after diagnosis to
$4,881 in the 7th year [21]. In Canada, Johnson et al. [52]
found the highest costs in the year of diagnosis, with
$7,635, up from $2,755 the year prior to diagnosis. In the
year after diagnosis, costs decreased to $4,273 and then
only increased slightly to $4,618 in year 10. In Germany
and Canada, costs related to complications or hospital visits
were the most important components and, in Germany,
increased steadily over time. In Canada, costs related to
prescriptions increased the most.
3.1.10 Country-Level Costs Prediction Studies
Four studies projected costs of diabetes over a certain pe-
riod of time [16, 17, 42, 80], making assumptions about the
future development of diabetes prevalence and population
ageing (see Table 4). For Canada, a 1.7-fold increase from
2000 to 2016 [16] and a 2.4-fold increase from 2008 to
2035 in diabetes healthcare costs was estimated [17].
Taking a healthcare system perspective, both studies found
Table 2 Relationship between direct costs and study characteristics
(robust linear regression)
Estimate Standard error
Constant 2,133 1773.922
GDP per capita ($) 0.045** 0.017
Estimation approach
Sum-all medical Ref.
Sum-diagnosis-specific -413.880 528.766
RB/matching -719.868 526.896
Survey -689.806 671.020
At least four costing components 702.966* 403.968
USA study 3,111.067*** 533.534
Year of study
\1995 Ref.
1995–1999 -1,744.799 1632.498
2000–2004 -816.647 1586.966
2005–2009 -1,021.685 1592.595
2010–2014 -2,744.739 1839.689
Study representative -598.670 409.070
Complications 666.803 414.727
R-squared adj. 0.559
N 70
Ref. reference category
*** p \ 0.01, ** p \ 0.05, * p \ 0.1
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that the estimated increase would be mostly driven by an
ageing population. For Australia, Davis et al. [42] esti-
mated a 2.5- to 3.4-fold increase in diabetes-attributable
healthcare costs from 2000 to 2051, depending on the un-
derlying assumptions about population ageing and diabetes
prevalence rates. For China, Wang et al. [80] extrapolated
total costs of diabetes from the year 2007 to 2030, esti-
mating the costs of diabetes to increase 1.8-fold, solely
accounting for the expected increase in prevalence.
3.2 The Impact of Diabetes on Employment Chances
and Productivity
Besides studies that determined the cost of diabetes by
costing related expenditures, another body of research has
investigated—using econometric techniques—the impact
of diabetes on ‘productivity’, a term used here to comprise
outcomes including employment probabilities and lost
work days and income or earnings. A recent study
Fig. 4 Direct and indirect cost
relation in studies estimating
total costs of type 2 diabetes.
The 45 line depicts the points
where direct and indirect costs
would be equal. Above the line,
direct costs are higher than
indirect costs and vice versa.
For better visibility, both
coordinate axes are expressed in
log scale. Refer to Table 7 for
country abbreviations
Table 3 Incidence studies on the costs of diabetes
References Country Time
horizon
Population Approach Results
[52] Canada 1992–2001 Incidence T2D pts from
Saskatchewan Health’s
administrative database in Canada
Sum-all
medical
Highest total healthcare costs at year of
diagnosis with CAN$7,343 ($7,635), then
increased from a low of CANS$3,880 ($4,034)
3 years after diagnosis to CAN$4,441 ten
years thereafter ($4,618)
[19] Colombia 32 years Hypothetical average Columbian T2D
pt
Sum-all
medical
Total lifetime costs (32-year period) of average
diabetes pt, including direct and indirect costs,
57.565 million Colombian pesos ($54,351)
[21] Germany 1995–2003 Newly diagnosed T2D pts from
randomly drawn practices across
Germany
Sum-all
medical
€1,288 ($1,635) for the first treatment year after
diabetes diagnosis and increased to €3,845
($4,880) in the 7th year
[73] USA 1997–1998 Women employed by nationwide
operating company and hypothetical
women above age 64 receiving
Medicare
RB/matching $282,973 incremental lifetime direct healthcare
costs, using incidence-based, steady-state
methodology
pt(s) patient(s), RB regression based, T2D type 2 diabetes
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systematically reviewed evidence on the impact of diabetes
on the ability to work, focusing on studies assessing the
impact of diabetes on early retirement, lost work hours,
absenteeism and presenteeism [97]. We focused par-
ticularly on studies exploring the impact of diabetes on
employment probabilities and earnings—both issues that
were not covered in the mentioned review—and we took a
more detailed look at the empirical challenges posed by the
issue of endogeneity (see the Appendix for a more detailed
discussion of endogeneity).
Tables 5 and 6 synthesize the relevant information from
the 22 identified studies on the effect of diabetes on em-
ployment and other labour market outcomes. Almost all
studies were conducted on HICs, mainly the USA (n = 13)
and European countries (n = 4). Only one study focused
on a LMIC, investigating the effect of diabetes on labour
income in China.
3.2.1 Employment Chances
Most studies examined the impact of diabetes on employ-
ment probability (n = 17), applying a range of econo-
metric techniques. These have evolved over time, and more
recent studies took into account the possibility that diabetes
might be endogenous: it is conceivable that especially
personal traits such as motivation and drive could influence
the propensity to develop type 2 diabetes as well as a
person’s job market opportunities. Further, being employed
or unemployed could also lead to changes in lifestyles due
to changes in income, stress or leisure time, that could
themselves affect the chances of developing diabetes [98].
Of the studies that tried to account for this problem [98–
103], the majority used an instrumental variables (IV)
technique. This approach allows for the consistent esti-
mation of the effect of diabetes on employment if a vari-
able can be found that is causally related to diabetes
without affecting the employment chances through any
other unobserved pathway apart from its effect on diabetes.
In the case of type 2 diabetes, all studies used the family
history of diabetes as an IV to exploit the fact that the
development of type 2 diabetes is much more likely for
individuals whose biological parents have also had dia-
betes. It is argued that, while controlling for education, age
and other observable demographic and socioeconomic
factors (e.g. wealth, regional and ethnic differences and the
number of children in the household), having a family
member with diabetes should not affect the person’s em-
ployment status or other labour market outcomes, while
strongly predicting the onset of type 2 diabetes.
Because IV estimation has worse asymptotic properties
than single equation regression results when endogeneity is
not an issue, studies tested for the existence of endogeneity
to determine which results to rely on for inference [98–
101]. Interestingly, the reviewed studies found diabetes to
be endogenous for either males [100] or females [98, 99],
but never for both. Further, the use of an IV sometimes
increased the estimated effect [99, 101], whereas in other
cases the effect turned insignificant [98, 100]. As a result,
no unambiguous conclusions can be drawn as to how en-
dogeneity affects diabetes and whether or not it causes
biased estimates. Most of the relevant studies also explored
whether accounting for body mass index (BMI) or other
diabetes-related chronic conditions would substantially al-
ter the result and found this not to be the case [98, 100,
104].
Overall, studies more commonly found a significant
adverse impact of diabetes on males, ranging from no ef-
fect in Canada [100] to a 19 % point reduction in Taiwan
[101]. Conversely, no effect was found for women in
Taiwan [101], Australia [102] or for Mexican Americans in
Texas [98]. However, a 45 % decrease in employment
chances was observed for women in the USA [99]. Ex-
tending the scope and looking at how diabetes duration
affected labour market outcomes using panel data from the
USA, one study found that the main adverse effect on
employment chances materialized within the first 5 years
Table 4 Country-level costs prediction studies
References Country Population Approach Time horizon Results
[42] Australia Australian population Sum-diagnosis
specific
2000–2051 If age- and sex-specific prevalence
remains unchanged ? 2.5-fold
increase; if age- and sex-specific
prevalence allowed to change as
well ? 3.4-fold increase
[16] Canada Canadian population Sum-all medical
costs
2000–2016 1.7-fold increase
[17] Canada Four Alberta Health and Wellness
databases
Sum-all medical
costs
2008–2035 2.4-fold increase
[80] China In patients and outpatients in 20
hospitals
Own survey 2007 and 2030
(projection)
Increase from $73 billion in 2007
to $132 billion in 2030 (1.8-fold
increase)
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Table 5 Studies estimating the relationship between diabetes and employment (2001–2014)
References Survey year Country Age
(years)
Effect on employment
Males Females
[103] 1999–2000 Australia [24 Exogenous: 10.8 % point reduction
to be in labour force; endogenous:
7.1 %points reduction; test
indicates endogeneity
Exogenous: 10 % points to be in
labour force; endogenous: 9 %
points reduction; test indicates
endogeneity
[102] 2001,
2004–2005
Australia 18–64 50–64: 11.5 % points less likely to
be in labour force; 18–49: 3.9 %
points less likely; all effects
increase when other chronic
diseases are present
No significant effect for diabetes
alone; significant negative effect
if other chronic diseases are
present
[100] 1998 Canada 15–64 Exogenous: 19 % points less likely
to be employed; endogenous: not
significant and positive; test
indicates endogeneity
Exogenous: 17 % points less likely
to be employed; endogenous: not
significant and positive and test
indicates exogeneity
[124] 1983–1990 Canada 18–64 With complications two times less likely to be in labour force; no
significant effect on employment for those in labour forcea
[71] 1992–1993 Sweden [24 14.2 % points higher retirement rate (22.9 vs. 8.7)a
[125] 2004 Sweden, Denmark, The
Netherlands, Germany,
Austria, Switzerland,
France, Italy, Spain,
Greece
50–65 For whole dataset: no effect of diabetes on being unemployed, but
increased OR of 1.33 on being retired. No information on effects by
countrya
[101] 2005 Taiwan 45–64 Exogenous: 9 % points less likely to
be employed; endogenous: 19 %
points less likely to be employed;
test on whole sample indicates
endogeneity
Exogenous: 11 % points less likely
to be employed, endogenous: not
significant and negative
[98] USA [44 Exogenous: 7.4 % points less likely
to be employed; endogenous:
10.6 % points less likely but test
indicates exogeneity
Exogenous: 7.5 % points less
likely to be employed;
Endogenous: no significant effect
found; test indicates endogeneity
[99] 2006 USA [19 at
diagnosis
Exogenous: 25.2 % less likely to
be employed; Endogenous:
45.1 % less likely to be
employed
[108] 1992–2000 USA 51–61 More likely to be retired in 1992 (adjusted OR 1.3). Over 8 years follow-
up spent 0.14 incremental years in retirementa
[105] 1996–1997 USA [44 7.5 % Points less likely to be
employed
No significant effect on
employment chances found
[110] 2008 USA 35–64 Diabetes negatively related to
employment (5 % points
reduction); better diabetes
management (A1c) positively
affects employment probabilities;
A1c lowering of 10 % increases
employment probability by
0.44 % points
No significant effect on
employment chances found
[126] 1992, 1994 USA 51–61 9 % Points less likely to work
without complications controlled
for, with complications controlled
for 7.1 % points less likely
5.9 % Points less likely to work
without complications controlled
for, with complications
controlled for 4.4 % points less
likely but not significant
[127] 1997–2005 USA 20–44 and
45–64
20–44: proportion with work limitations 3.1 % higher; 45–64: proportion
not working is 8.1 % higher; the proportion work disabled is 3.4 %
higher; proportion with work limitations is 5.7 % higher (all vs. similar
age group without diabetes)a
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after diagnosis for men and 11–15 years after diagnosis for
women [104].
3.2.2 Productivity
For earnings, no effect was found for Mexican-American
men in Texas [105], while the highest loss was found for
women in the USA ($21,392 per year) [99]. Again looking at
diabetes duration, a wage penalty was only found for USA
men 6–10 years after diagnosis, reducing their wage by
about 18 % [104]. The only study on a non-HIC, China, tried
to tease out the psychological effect of a diabetes diagnosis
on subsequent labour income, finding a reduction of 22 % in
income for males, but not for females. Further, those with
glycated haemoglobin (HbA1c) between 8 and 10 % expe-
rienced the most severe income penalty (28 %). The study
further showed that the adverse effect of a diabetes diagnosis
was concentrated among the poorest third of the study
population [106]. Another study investigated the effect on
earning losses for caregivers of people with diabetes in the
UK, finding a reduction of $2,609 per year, while the person
with diabetes experienced a loss of $1,744 per year [107].
For income, a reduction of $6,250 per year was found for
older USA adults who had been followed between the years
1992 and 2000 [108]. In terms of lost workdays and work
hours due to diabetes, the effects ranged from no impact on
lost work days on older people [108] and females in the USA
[99] to 3.2 lost work days in a USA population within a
2-week period if complications were present [109].
In terms of the methodology used, these studies tended
to rarely account for endogeneity, and they mostly used
standard regression or matching methods to estimate the
impact of diabetes. Three studies [99, 105, 110] corrected
for the possibility of a sample selection bias, to account for
systematic differences between the working population and
the overall population. Only one study additionally applied
IV methods and found diabetes to be endogenous, so that
its effects on earnings were dramatically understated using
naive regression results [99]. For working hours and days
missed due to illness, the same study found no indication of
endogeneity. Only one study applied an approach other
than IV to account for endogeneity, using a difference-in-
difference model and exploiting a recent diagnosis of dia-
betes, which was the result of the collection of biomarkers
in the survey used, as a natural experiment to measure how
income developed between those who were newly diag-
nosed and those without diabetes in the years following
diagnosis [106].
4 Discussion
The objectives of this systematic review were to identify
new evidence on the economic impact of type 2 diabetes
that emerged since 2001 and extend the scope of the review
by including studies on the labour market impact of dia-
betes. We identified studies from a great variety of coun-
tries, with large differences in cost estimates across and
within countries.
4.1 General Findings and Developments Since
the 2004 Review of Diabetes COI Studies
An obvious development since the last review is the
emergence of COI studies on LMICs. The economic bur-
den related to diabetes found in these studies indicated a
strong direct impact on those affected by diabetes. This is
reflected in the substantial burden of OOP treatment costs
incurred by patients [10, 12, 26, 67, 80, 83, 85, 87, 88, 91,
92], with considerable proportions of the annual income
being spent on diabetes care. This relative cost burden was
generally higher for people with relatively lower household
incomes [83, 85, 91]. Health insurance coverage had some
protective effects against OOP expenditures, but mainly for
those with higher incomes, while the poor often lacked
coverage [83, 85, 91]. Once people were covered by health
Table 5 continued
References Survey year Country Age
(years)
Effect on employment
Males Females
[128] 1990–1995 USA Unemployment rate for pts with diabetes was 16 % compared with 3 %
among matched comparison groupa
[109] 1989 USA [29 at
diagnosis
3.6 % less likely to be employed (exogenous), 12 % for those with
complicationsa
[104] 1979–2010 USA [14 Average reduction of employment
probability of 28 % points;
strongest employment penalty in
first 5 years after diagnosis
Average reduction of employment
probability of 36 % points;
strongest employment penalty in
first 15 years after diagnosis
A1c glycated haemoglobin, OR odds ratio, pts patients
a No gender differentiation in study
T. Seuring et al.
Table 6 Studies estimating the relation between diabetes and other productivity outcomes (2001–2014)
References Survey
year
Country Age (years) Effect on other productivity outcomes
Males Females
[124] 1983–1990 Canada 18–64 Effect on earnings only when complications are present: reduced to 72 % of total
income of controlsa
[106] 2009, 2011 China Not given 16.3 % decrease in annual income for newly diagnosed diabetics in 2011. Impact
more significant for males and people with A1c levels between 8.0 % and 10.0 %,
leading to a 22.0 % and 28.0 % decrease in annual income, respectively. Also
effects are stronger for those in lower income quintiles
[129] 1989–2007 France Males
40–50,
females
35–50 in
1989
1.7 HR to transition from employed to disabled, 1.6 HR to be retired, 7.3 HR to be
dead; between age 35 and 60 each person with diabetes lost 1.1 years of time in
workforcea
[130] 2010–2013 The
Netherlands
45–64 Diabetes reduced work ability measured using WAI by 2 %. No significant effect on
productivity was founda
[71] 1992–1993 Sweden [24 9.4 more sick daysa
[107] 1999 UK \65 $1,744 lost earnings per year with diabetes; $2,609 for carers of people with diabetesa
[99] 2006 USA [19 at
diagnosis
Exogenous: $3,118 loss in earnings
per year, Endogenous: $21,392;
Exogenous: 2 working hours less
per week, no significant effect on
missed workdays per year,
endogenous: no significant effect
on working hours or workdays
missed
[108] 1992–2000 USA 51–61 Lost income of $50,004 from 1992 to 2000 per capita or $6,250 per year, for whole
US population of same age $85.6 billion or $10.7 billion per year; people with
diabetes more likely to have taken sick days in 1992 (adjusted OR 1.3)a
[131] 2002 USA Working
age
No significant effect on work daysa
[105] 1996–1997 USA [44 No significant effect on earnings Women with diabetes earn 84 %
less
[110] 2008 USA 35–64 Wages reduced by 0.74 % due to diabetes; for
every 10 % reduction in A1c wages rise by
0.62 %. A1c [8 was related to decreasing
wages
No significant effect of diabetes on
female earnings; no effect of
blood sugar management for
women, A1c levels just below 6 to
just above 7 were related to lower
wages
[132] 2005–2009 USA [16 Lost earnings per year of $2,221a
[126] 1992, 1994 USA 51–61 No significant effect on number of work days 2.5 more lost workdays per year
[128] 1990–1995 USA 71 % of those with diabetes had an annual income of less than $20,000 compared with
59 % of the matched respondentsa
[109] 1989 USA [29 at
diagnosis
No significant effect on work days for T2D, for
those with complications 3.2 days lost within
2 weeks
[133] NA USA [45 For every dollar of labour income lost by adults with diabetes, a further income
reduction of $0.48 occurs in the community. Total output reduction for upper bound
estimate is $300 million for the local economya
[104] 1979–2010 USA [14 No general effect of T2D on wages; some
evidence of wage penalty of about 18 %
6–10 years after diagnosis
No strong evidence found for wage
penalty for females
A1c glycated haemoglobin, HR hazard ratio, OR odds ratio, T2D type 2 diabetes, WAI Work Ability Index
a No gender differentiation in study
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insurance, their risk of incurring catastrophic expenditures
decreased significantly [10]. An important cost factor that
was predominantly investigated in studies on LMICs were
non-medical costs for transportation, informal healthcare or
food, which were found to considerably add to the expe-
rienced diabetes cost burden [67, 80, 81, 88, 92].
In terms of the costing methodology applied in COI
studies, the number of studies estimating the excess costs of
diabetes increased since the Ettaro et al. [3] review. Those
studies either used regression analysis or matching to adjust
for the differences between people with diabetes and those
without, accounting at least for age and gender, but often
also for other socioeconomic, geographic and demographic
differences. Other widely used approaches to estimate direct
healthcare costs from the perspective of the healthcare sys-
tem or private insurance included the disease-attributable
and—slightly less frequently—the attributable-fraction ap-
proach. For cost assessment in LMICs, studies often either
estimated total healthcare costs or carried out self-admin-
istered surveys. While Ettaro et al. [3] suggested an in-
creased use of disease-attributable approaches to arrive at
more exact estimates of the costs of diabetes, the evidence
found in this review indicates that using an incremental cost
approach via matching or regression analysis could provide
more accurate results, due to its ability to capture costs
otherwise not directly traceable to diabetes. Nonetheless, the
use of the estimation technique always hinges on the avail-
ability of appropriate data, with regression or matching
analyses requiring information on people without diabetes to
be used as a control group. Therefore, the estimation ap-
proach needs to be tailored to the available data.
Compared with the evidence reviewed by Ettaro et al.
[3], the field has generally advanced with respect to the
analysis of costs in different ethnic and age groups. Two
studies investigated differences between racial groups in
the USA, showing that while ethnic minorities spend less
on diabetes healthcare than Whites, this difference seems
to be mainly based on differences in access to care between
Whites and Blacks or Hispanics [39, 50]. In terms of age,
studies found an increase in healthcare costs with age as
well as with, in some cases, the duration of diabetes. A
recurring problem was that many studies did not distin-
guish between diabetes types, making it difficult to exactly
attribute the costs to the respective diabetes types.
To explore the reasons for the wide heterogeneity in
direct cost estimates across studies, we performed a re-
gression analysis, which indicated that an important de-
terminant for the cost variation across countries could be
the economic wealth of the country (proxied by GDP per
capita), similar to what was found in a review of indirect
costs of various chronic diseases [111], possibly due to
differences in the availability and affordability of diabetes
care between HICs and LMICs [112, 113].
Further, studies on the USA seem to estimate consis-
tently higher costs than studies on other countries, even
when accounting for differences in GDP per capita. The
higher direct costs of diabetes estimated for the USA are in
line with the generally higher healthcare expenditures in
the USA compared with countries with similar income
levels, and could be the result of exceptionally high service
fees [8] and prices paid in the USA healthcare system [114,
115].
Because of the small sample size on which our analysis
was based, these results must be interpreted with caution,
and other factors could still be important. For instance,
other evidence suggests that different costing approaches
have a considerable effect on diabetes cost estimates [51,
60]. Furthermore, the perspective taken, different data
sources and populations investigated and decisions on the
cost components included are likely important in explain-
ing within-country heterogeneity. In particular, the inclu-
sion of diabetes complications and decisions about which
complication(s) to include, as well as the extent to which
costs for these diseases are attributable to diabetes, can
significantly affect the results. Not all studies in the review
provide extensive information about how they include
complications and some do not include them at all.
Finally, the quality of the data used could have affected
the cost estimates. Many studies in LMICs relied on self-
reported data from small household surveys, limiting their
generalizability and leading their results to be prone to
recall bias. Further, these studies often identified people
with diabetes via their use of healthcare institutions, which
excluded a potentially important section of the population
in LMICs unable to access formal care, possibly leading to
an overestimation of the average diabetes-related costs.
4.2 Labour market studies
Turning to the effects of diabetes on the labour market, the
existing studies showed, almost consistently, with the ex-
ception of Canada [100] and one study on the USA [102],
that the employment probabilities of men were affected
more adversely by the disease than those of women.
However, while most studies have tried to tentatively ex-
plain these gender differences, the reasons for this have not
been investigated in depth. The studies also showed that,
when interpreting this research, it is important to consider
whether a study has tried to account for unobservable
factors or reverse causality, as otherwise the results might
be misleading. Nonetheless, all studies using IV techniques
used similar instruments to achieve identification, provid-
ing scope for further research using different identification
strategies to further explore how endogeneity might affect
the results. What has been apparent is the lack of research
on labour market outcomes of diabetes in LMICs, with
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only one study investigating the effect of diabetes on
labour income in China [106]. This deficit might be due to
a limited availability of suitable data sources containing
sufficient information to allow for a similar investigation of
the topic.
The potential for rich, good-quality data sources to aid
the investigation of the economic impact of diabetes can be
illustrated by the several studies that used data from the
Lower Rio Grande Valley in Texas. These studies
demonstrate the evolution of methodology and data from
the use of single equation regression models [105] to the
use of IV methods [98] and—finally—biometric data on
blood glucose values [110]. While the first two methods
allowed the investigation of the general effect of diabetes
on employment chances, the latter was able to assess the
impact according to how diabetes was managed by the
patient, as proxied by the measured biomarkers. The study
found that the main adverse effect was due to having dia-
betes regardless of how it was managed and that im-
provements in management only had minor positive
effects. The authors concluded that investments in the
prevention of diabetes would likely be more effective than
improved diabetes management.
The latter study and the study by Liu and Zhou [106]
also show how biometric data (e.g. blood glucose values)
can be used to arrive at a deeper understanding of the
economic effects of diabetes. This information makes it
possible to investigate the impact of diabetes according to
the severity of the disease and also allows for the consid-
eration of previously undiagnosed people with diabetes,
increasing the policy relevance of the research.
4.3 Comparison of COI and Labour Market Studies:
Common Themes and Lessons Learnt
The results of both fields, COI and labour market studies,
show a considerable adverse impact of diabetes in terms of
costs to society, health systems, individuals and employers
and in terms of a reduction in the productive workforce and
productivity in general. Both research strands particularly
indicate that the adverse effects of diabetes increase with
diabetes duration as well as with the severity of the disease,
judged by the high complication costs estimated in COI
studies and the larger employment and income penalties for
those with a longer disease duration or higher blood glu-
cose levels.
Nonetheless, several lessons can be learned for each
field from advancements in the other field. Future COI
studies would, for instance, benefit from the more frequent
use of biomarker data. This would allow for a more precise
analysis of the costs of diabetes according to the severity of
the disease and help inform researchers and policy makers
about the possible economic effects of achieving certain
treatment goals, e.g., a reduction in blood glucose values.
Also, and in contrast to the labour market outcomes
literature, the endogeneity problem has hitherto not been
addressed in any form in studies estimating direct health-
care or productivity costs, despite it being an equally im-
portant challenge in this domain. A possible bias could
arise if some people developed diabetes as a result of an
unobserved accident or illness, likely resulting in an
overestimation of the costs. Endogeneity could also be
introduced if people with diabetes became poorer as a re-
sult of the disease and consequently were not able to spend
as much on their treatment as they would like to, leading to
an underestimation of the true monetary cost of diabetes.
Furthermore, an endogeneity bias would be introduced if
diabetes was correlated with poverty so that diabetes
prevalence would be disproportionately high in subgroups
with less resources and consequently less access to care.
This would lead to an underestimation of the healthcare
costs of diabetes. Endogeneity in COI studies has recently
been addressed for the estimation of healthcare costs of
obesity, suggesting that direct costs would have been un-
derestimated, had the study not accounted for endogeneity
[116]. It appears that, on the basis of the studies identified
in our review, a similar and worthwhile approach could and
should be applied to the case of type 2 diabetes.
Yet the labour market studies also stand to gain from
adopting certain approaches that are more common in COI
studies. To date, only few labour market studies have used
the incidence approach found for COI studies to follow
people with diabetes over a certain time period from their
diagnosis onwards, in order to further explore how the
effect of diabetes on employment and productivity mea-
sures develops over time. So far, only one study has done
this using a rigorous econometric panel data analysis [104],
but more similar studies using other populations would be
helpful to establish patterns reflecting the impact of dia-
betes on the labour market along the continuity of disease
duration.
Some further recommendations may be derived for fu-
ture COI and labour market studies on diabetes:
1. For COI studies, the estimation of incremental costs—
wherever possible—appears to be most suitable for
diabetes, as it more accurately accounts for costs of co-
morbidities and for less obviously related disease costs
[51, 60]. More information that can guide researchers
in their choice of methods already exists and should be
referred to when performing a COI study [95].
2. If possible, the use of convenience samples of people
with diabetes visiting a healthcare institution should be
avoided, particularly in LMICs, as it excludes those
not able or willing to visit a clinic for treatment due to
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economic reasons, leaving out a potentially important
proportion of diabetes patients.
3. The interpretation of the COI results always hinges on
the amount of information provided about, among
others, the aim of the study, the perspective adopted
and the cost components included as well as the
estimation approach used. A discussion of how these
choices might affect the estimates should also be part
of every COI study. Researchers should therefore
consult available guidance from the literature that sets
out what information should ideally be included in a
COI study [96] to increase the transparency and
usability of their research.
4. For labour market studies, more evidence from LMICs
is needed. There is scope for exploring existing
household datasets from LMICs that contain informa-
tion on diabetes [117]. In some cases, panel data are
(or may come) available, which would allow the
investigation of the effects of diabetes over time as
well as improve the degree of causal inference by
controlling for unobserved heterogeneity.
5. As for labour market studies, other ways of achieving
identification should be explored to reduce the reliance
on IV methods using the family history of diabetes as
the sole instrument. The increasing richness of infor-
mation provided in recent data sets could be used to
this effect, also taking into account other quasi-
experimental econometric methods [118].
4.4 Limitations
A possible limitation of this review is the decision to re-
frain from excluding studies based on certain quality cri-
teria, such as study design, costing methodology, sample
size or reporting standards. This might have resulted in the
inclusion of lower-quality studies with less reliable esti-
mates, compromising the comparability across countries,
particularly between LMICs and HICs, as study designs
differed considerably. On the other hand, our overarching
objective was to ensure a truly globally comprehensive
overview of the literature on the economic impact of dia-
betes, including evidence from LMICs, which, for reasons
often beyond the control of the researchers, may have been
of limited quality and thus would have been excluded had
we applied stringent quality benchmarks. Further, any at-
tempt to apply a quality threshold would have faced the
challenge of dealing with the absence of a formal checklist
to follow in critically appraising the quality of COI studies.
Rather than interpreting it as a limitation, we see the
identification and synthesis of LMIC studies as a unique
added value of this review, when compared to the Ettaro
et al. [3] review published in 2004.
Notably, we also abstained from any language restrictions,
which would have particularly excluded evidence from
Spanish speaking and Eastern European countries. Taken
together, these factors have resulted in a large number of
included studies, allowing for an (albeit exploratory) statis-
tical investigation of the heterogeneity in diabetes cost esti-
mates as a complement to the narrative analysis. We therefore
feel that the advantages of refraining from too stringent in-
clusion criteria more than outweigh the possible negative
consequences of including potentially lower-quality studies.
Further, our search was limited to studies after the year
2000. While for COI studies a previous review covered the
literature until 2000, this is not the case for the literature on
labour market effects of diabetes and we therefore cannot
exclude the possibility of having missed some relevant (if
old) studies.3
5 Conclusion
This review has provided an updated and considerably
expanded picture of the literature on the global economic
impact of type 2 diabetes. The results show a considerable
impact of diabetes in terms of costs to society, health
systems, individuals and employers and in terms of a re-
duction in the productive workforce and productivity in
general. Studies on the costs of diabetes now provide evi-
dence from HICs as well as LMICs, using a variety of
study designs to estimate the costs of diabetes. The evi-
dence indicates a particularly strong and direct economic
impact of type 2 diabetes on people’s livelihoods in lower-
income settings. Studies on labour market outcomes so far
have been confined, almost exclusively, to HICs, leaving
space for further studies in LMICs to provide additional
evidence of the effect of diabetes in these countries. An
issue not yet covered in diabetes COI studies—in striking
contrast to labour market outcome studies—has been the
possible bias introduced by endogeneity, providing an op-
portunity for advancing research in this area.
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Appendix: A1. What is Endogeneity?
Endogeneity is a statistical problem that occurs in regres-
sion models if the assumptions about the flow or direction
of causality are incorrect. If endogeneity is ignored, it
could be that claims about causality between two variables
or the magnitude of the effect are false. In general, one can
only be certain about a causal relationship of the effect of
x on y if the following three conditions are met [119]:
• y follows x temporally
• y changes as x changes (and this relationship is
statistically significant)
• no other causes should eliminate the relation between
x and y.
Three major causes of endogeneity violate the condi-
tions above.
Omitted Variables
When a regression is run to determine the causal effect of
variable x on variable y, but there are unobserved vari-
ables that affect variables x or x and y simultaneously,
the estimated effect of x on y will be biased. For the case
of type 2 diabetes and employment chances, there is the
danger that, for example, personal traits like ambition,
which are hard to observe, could influence the probability
of developing type 2 diabetes through their effect on a
person’s lifestyle, but they could also simultaneously af-
fect the chances of employment through their influence
on a person’s determination to find work or to perform
well at work. If we are not able to control for this, then
our estimate of the effect of diabetes on employment
chances might, at least partially, represent the effect of
personal traits on employment chances. As a result, our
estimate of the effect of diabetes is biased and does not
represent the true size of the relationship between the two
variables.
Simultaneity
Simultaneity is present if our outcome variable y and our
variable of interest x influence each other simultaneously,
so that y not only is affected by x but x is also affected by
y. In the case of type 2 diabetes and labour market out-
comes, not only could diabetes influence employment
chances or work-related income, but also resulting changes
in lifestyle due to employment or an increase in income
could affect the probabilities of developing diabetes. Due
to an increase in income, people could change their diet or
change towards a less active lifestyle, which in turn would
make them more likely to develop type 2 diabetes.
Measurement Error
Measurement errors occur when the independent variable
x is imprecisely measured. Here, this would be the case if
people in a survey did not remember whether they have
been diagnosed with type 2 diabetes and gave an incorrect
answer.
Several solutions to the problem of endogeneity exist,
but only the use of IV techniques has the potential to deal
with all three causes of endogeneity at once. Endogeneity
is a problem, because the variable of interest, here diabetes,
is correlated with the error term of the estimated model,
which includes all omitted variables as well as the effect of
y on x and, if measurement error is present, the true values.
To do this, one needs to find a suitable instrument that
needs to fulfil the following conditions:
• it must be causally related to the endogenous variable x,
and
• it should not be correlated to the dependent variable
y other than through its correlation with x.
This instrument is then used in a first regression to ob-
tain predicted values of the problematic endogenous re-
gressor. Because the instrument is not correlated with the
error term, these predicted values of the endogenous vari-
able will also be uncorrelated and can then be used in a
second regression to predict the dependent variable y. The
estimated coefficients of this second stage can then be re-
garded as consistent estimates.
In the case of type 2 diabetes and labour market out-
comes, an instrument has to predict the development of
diabetes without being otherwise causally related to any of
the labour market outcomes, be it employment chances,
wages or some other measure of productivity. The instru-
ment of choice so far has been the family history of dia-
betes. It has been shown that a considerable part of the risk
of developing type 2 diabetes is hereditary [120–122]. This
fact is exploited when the instrument is used and it is
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assumed that this is the only pathway through which a
family history of diabetes affects a person’s diabetes risk,
and also that, for example, parental diabetes does not affect
the person’s labour market outcomes directly.
The most common estimation techniques for the esti-
mation of IV regressions are the linear IV model and the
bivariate probit model. The latter is often deemed more apt
for models where both the outcome and the IV are binary,
so either 0 or 1, which is the case for employment as an
outcome variable as well as diabetes family history as an
instrument. Nonetheless, there is some discussion in the
econometrics literature regarding the best method to esti-
mate these cases, as it has also been argued that, because
the linear IV technique does not depend on the assumption
of normality of the error terms, in contrast to the bivariate
probit model, its results are more reliable in the case of
non-normality, but can sometimes lead to imprecise esti-
mators, which can no longer be interpreted meaningfully
[123]. Both methods can be found in the reviewed papers.
A2. Country Codes
See Table 7.
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